Priority One Canine acquires Bio Detection K9
Priority One Canine (P1K9), known worldwide for its elite canine protective strength, is entering into a joint venture with French biotechnology company Neovacs using emerging technology to improve canine services and safety. The acquisition of the American company Bio Detection K9 continues the efforts of the French government, aligning forces in the fight against COVID-19 and other pathogens.
“We are delighted to have formed a joint venture with French company Neovacs, continuing the efforts of the French government to roll out a national COVID-19 detection program using K9 assets,” said Wade Morrell, CEO of P1K9 . “Seven years after our first appearance on Shark Tank as a startup, and millions of dollars in sales later, P1K9 is extremely proud to complete this deal with the support of this COVID-focused biotech company. “
Bio Detection K9 specializes in the scientific research, development and implementation of canine detection services that respond to current threats such as COVID-19 and emerging threats of additional biological contagions. The company intends to deploy the K9 COVID detection assets worldwide, which will allow the general population to resume a life in which they can safely attend social gatherings and much-needed sporting events. .